Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | GABRP | O00591 | 1/20 | 0.51 |
| ▸ | GABRD | O14764 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.51 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.51 |
| ▸ | GABRE | P78334 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17338654 | 0.86 | CASP3 (0.54) | MAOBACHEMAOACASP3SENP8 | |
| SCHEMBL4306909 | 0.86 | MAOB (0.52) | MAOBMEN1KMT2AACHEALDH1A1 | |
| SCHEMBL491943 | 0.82 | KDM4E (0.50) | MAOBMEN1KMT2AGABRA1GABRG2 | |
| SCHEMBL17338655 | 0.81 | MAOB (0.48) | MAOBMEN1KMT2AACHEMAOA | |
| SCHEMBL8308126 | 0.81 | MAOB (0.48) | MAOBMEN1HSP90AA1KMT2AGABRA1 | |
| SCHEMBL17338667 | 0.80 | MAOB (0.46) | MAOBACHEMAOACASP3SENP8 | |
| SCHEMBL492496 | 0.79 | AKR1B1 (0.54) | MAOBMEN1HSP90AA1KMT2AALDH1A1 | |
| SCHEMBL8304336 | 0.78 | MAOB (0.51) | MAOBMEN1KMT2AACHEALDH1A1 | |
| SCHEMBL1572943 | 0.77 | KDM4E (0.52) | MAOBKMT2AGABRA1GABRG2GABRB3 | |
| SCHEMBL30174438 | 0.77 | KDM4E (0.52) | MAOBKMT2AGABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170121315-A1 | HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-04 | — | — | US | disclosed |
| US-20170121315-A1 | HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-04 | — | — | US | disclosed |
| US-20170121315-A1 | HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-04 | — | — | US | disclosed |
| WO-2015189117-A1 | HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015189117-A1 | HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-17 | — | — | WO | disclosed |
| US-8058276-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| US-20090030009-A1 | Heterobicyclic Carboxamides as Inhibitors for Kinases | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
| EP-1996578-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008009487-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030009-A1 | Heterobicyclic Carboxamides as Inhibitors for Kinases | PHKG1, MAP3K20, CDK2 | MAOB 1931/4885MEN1 2277/4885HSP90AA1 1051/4885 |
| US-20170121315-A1 | HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF | ABAT, HADHB, CYP11B2 | MAOB 376/4885MEN1 4601/4885HSP90AA1 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.